SCS Head of Surgery and study co-author Professor Julian Smith |
A world-first study led by Monash University clinician-researchers shows that patients
who take aspirin before heart surgery are at no greater risk of bleeding or
complications.
Published last week in The New England Journal of Medicine,
the collaborative research study led by Professor Paul Myles from the Central
Clinical School investigated whether stopping or continuing aspirin before
coronary artery surgery posed more risks or benefits.
Most patients with coronary artery
disease receive aspirin for prevention of heart attack, stroke, and death. However
aspirin poses a bleeding risk for patients undergoing surgery, and prior to
this study it was unclear whether aspirin should be stopped before coronary
artery surgery.
Professor Myles, Chair of Anaesthesia and
Perioperative Medicine, Alfred Hospital, said until recently, ceasing aspirin
five to seven days before surgery has been traditional practice in most cardiac
surgical centres.
“Until now, conflicting guidelines from expert professional
organisations highlight the lack of evidence to determine if the increased risk
of surgical bleeding could be outweighed by a beneficial effect of aspirin,”
said Professor Myles.
Study co-author and Head of Surgery at the
School of Clinical Sciences at Monash Health Professor Julian Smith said
“The study found the use of aspirin, as compared with placebo, before coronary artery
surgery did not reduce the risk of death and thrombotic complications.
“Preoperative
aspirin exposure did not increase surgical bleeding, transfusion requirements
or need for re-operation and there is therefore no reason to stop aspirin before coronary artery surgery,” Professor
Smith added.
The researchers
evaluated the benefits and bleeding risks of aspirin at a dose of 100mg, the
dose deemed to have the strongest evidence of efficacy balanced against a low
risk of bleeding complications.
“We wanted to
determine whether it was best to stop or continue aspirin in patients
undergoing heart surgery,” said co-author and Head of School of Public
Health and Preventive Medicine Professor John McNeil.
Professor McNeil is also Co- Principal Investigator to the ASPirin in Reducing Events in the Elderly (ASPREE) trial, investigating whether daily low-dose aspirin prevents or delays the onset of disease, such as coronary artery disease, and if the potential benefits outweigh the risks in healthy older people.
Professor McNeil is also Co- Principal Investigator to the ASPirin in Reducing Events in the Elderly (ASPREE) trial, investigating whether daily low-dose aspirin prevents or delays the onset of disease, such as coronary artery disease, and if the potential benefits outweigh the risks in healthy older people.
“Stopping
aspirin five to seven days before surgery increases thrombotic risk
before the benefits of bypass grafting can be achieved and sometimes surgery is
cancelled or delayed exposing the patient to increased thrombotic risk,” added
Professor Myles.
“Withdrawal of aspirin in patients scheduled for surgery to
reduce bleeding risk could be harmful.”
2100 patients across five countries in 19 participating
hospitals were enrolled and randomly assigned to the research project.